TScan Therapeutics, Inc. (TCRX)
- Sector
- Biotechnology
- Last price
- $0.19
- As of
Kresmion compiles this page from TCRX's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
TScan Therapeutics, Inc. (TCRX): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-10-16.
See the full TCRX dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for TCRX on one page. Preview it with sample data, then open it live with a free account.
Preview the TCRX dossierActive events for TCRX
- high13F: funds added
3 tracked funds increased TCRX this 2026Q2, institutional consensus
- mediumEarnings below estimates
Q2-2026: Missed consensus by 5.0%, EPS $-0.23 vs $-0.219 estimate
- high13F: large increase
CITADEL ADVISORS LLC added +520% to TCRX (2026Q2)
- high13F: large increase
D. E. Shaw & Co., Inc. added +72% to TCRX (2026Q2)
- high13F: large increase
TWO SIGMA INVESTMENTS, LP added +61% to TCRX (2026Q2)
FREE, NO ACCOUNT
Every event on TCRX, as it fires
You are seeing 5 of 13 events recorded on TCRX since 2026-05-30.
The five above landed across 3 days. The other 8 were recorded on 3 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
TCRX positions held by the managers we follow (2026Q2)
What the managers we follow bought and sold in Q2 2026
| Manager / security | Market value | % of reported value |
|---|---|---|
| TWO SIGMA INVESTMENTS, LP FundCUSIP 89854M101 · 2026Q2 | $1.9M | 0.00% |
| RENAISSANCE TECHNOLOGIES LLC FundCUSIP 89854M101 · 2026Q2 | $1.3M | 0.00% |
| MILLENNIUM MANAGEMENT LLC FundCUSIP 89854M101 · 2026Q2 | $1.1M | 0.00% |
| CITADEL ADVISORS LLC FundCUSIP 89854M101 · 2026Q2 | $989K | 0.00% |
| D. E. Shaw & Co., Inc. FundCUSIP 89854M101 · 2026Q2 | $537K | 0.00% |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. The share of reported value is each position's value over the sum of the values that manager reported for the quarter; option lines are not in that sum, as on each fund page. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, TCRX
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
Going concern statement
TCRX's 10-Q filed Aug 12, 2026 states:
We have identified conditions that raise substantial doubt about our ability to continue as a going concern.
Read the 10-Q on SEC EDGAR Every company with a going concern statement
More data on TCRX
TCRX mentioned in Kresmion daily briefs
TCRX against its peers
TCRX's operating margin of -1315.4% ranks in the 55th percentile of 9 Biotechnology sub-industry peers, fiscal periods ending between 2025-03-31 and 2026-06-30.
| Metric | TCRX | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 10.3M USD | 244857 USD | 88 | 12 |
| Gross margin | n/a | 64.8% | n/a | 5 |
| Operating margin | -1315.4% | -1315.5% | 55 | 9 |
| Net margin | -1256.8% | -1300.7% | 55 | 9 |
| Return on equity | -105.4% | -180.6% | 76 | 18 |
Peers (22): TVRD, PASG, BCDA, AEON, DARE, ADIL, CLGN, SYBX, DYAI, CLRB, GUTS, INTI, ABOS, BIVI, ASBP, PBM, BOLT, ANEB, PTN, LSTA, CKDXF, HIND. Left out: QNTM (no annual filing), HOOK.D (period gap), VICP (period gap). Fiscal periods ending between 2025-03-31 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (TCRX: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Cite this data
Kresmion counts the managers it follows that reported a non-option position in TCRX on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on TCRX in the last 180 days.
Upstream: SEC EDGAR filings for TCRX
Kresmion, "TScan Therapeutics, Inc. (TCRX) institutional holdings and SEC filings", data as of 2026-10-16, https://kresmion.com/research/TCRX. Upstream data: SEC EDGAR filings for TCRX.
Link to this data (HTML):
<a href="https://kresmion.com/research/TCRX">TScan Therapeutics, Inc. (TCRX) institutional holdings and SEC filings (Kresmion)</a>
Writing about this? Press contact and ready-to-quote figures
Follow TCRX on a live board
Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to TCRX for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.